These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 36825202)

  • 1. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
    Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
    Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-omics pan-cancer study of cuproptosis core gene
    Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
    Front Immunol; 2022; 13():981764. PubMed ID: 36605188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.
    Yao Y; Chen H; Lou M; Chen T
    Front Genet; 2023; 14():1071694. PubMed ID: 36755576
    [No Abstract]   [Full Text] [Related]  

  • 4. Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis.
    Yang L; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Front Pharmacol; 2022; 13():938134. PubMed ID: 36210836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker.
    Zhang C; Zeng Y; Guo X; Shen H; Zhang J; Wang K; Ji M; Huang S
    Front Genet; 2022; 13():923737. PubMed ID: 35991547
    [No Abstract]   [Full Text] [Related]  

  • 6. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 8. Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma.
    Lu H; Zhou L; Zhang B; Xie Y; Yang H; Wang Z
    Front Med (Lausanne); 2022; 9():939776. PubMed ID: 36523779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The signature genes of cuproptosis associates with tumor immune microenvironment and predicts prognosis in kidney renal clear cell carcinoma.
    Liu S; Lv S; Li X; Lu W; Chen S
    Front Oncol; 2024; 14():1409620. PubMed ID: 39206152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer.
    Li X; Dai Z; Liu J; Sun Z; Li N; Jiao G; Cao H
    Front Genet; 2022; 13():969856. PubMed ID: 36226187
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification and validation of transferrin receptor protein 1 for predicting prognosis and immune infiltration in lower grade glioma.
    Wu H; He H; Huang J; Wang C; Dong Y; Lin R; Cheng Z; Qiu Q; Hong L
    Front Mol Neurosci; 2022; 15():972308. PubMed ID: 36483569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Cuproptosis-Related Prognostic Model and the Hub Gene
    Zhang K; Yang W; Zhang Z; Ma K; Li L; Xu Y; Qiu J; Yu C; Zhou J; Cai L; Gong Y; Gong K
    J Oncol; 2022; 2022():2124088. PubMed ID: 36536785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis.
    Liu Z; Miao J
    Sci Rep; 2023 May; 13(1):7926. PubMed ID: 37193786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and immunological role of cuproptosis-related protein FDX1 in pan-cancer.
    Xiao C; Yang L; Jin L; Lin W; Zhang F; Huang S; Huang Z
    Front Genet; 2022; 13():962028. PubMed ID: 36061184
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulation, genomics, and clinical characteristics of cuproptosis regulators in pan-cancer.
    Zhou C; Li C; Zheng Y; Huang X
    Front Oncol; 2022; 12():934076. PubMed ID: 36387247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cuproptosis-related gene
    Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
    Front Immunol; 2022; 13():999823. PubMed ID: 36225932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of RNMT as an immunotherapeutic and prognostic biomarker: From pan-cancer analysis to lung squamous cell carcinoma validation.
    Huang S; Tan C; Zheng J; Huang Z; Li Z; Lv Z; Chen W; Chen M; Yuan X; Chen C; Yan Q
    Immunobiology; 2024 Sep; 229(5):152836. PubMed ID: 39018675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of POFUT1 as a prognostic predictor in low-grade gliomas: Immune microenvironment insights from a pan-cancer analysis.
    Yu F; Lou S; He H; Zhou Y
    Heliyon; 2024 Mar; 10(5):e27004. PubMed ID: 38463813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.